Patents by Inventor Holger Kost

Holger Kost has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell-derived viral vaccines with low levels of residual cell DNA
    Patent number: 11466257
    Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 11, 2022
    Assignee: Seqirus UK Limited
    Inventors: Jens-Peter Gregersen, Holger Kost
  • CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA
    Publication number: 20200377864
    Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
    Type: Application
    Filed: April 9, 2020
    Publication date: December 3, 2020
    Inventors: Jens-Peter GREGERSEN, Holger Kost
  • Cell-derived viral vaccines with low levels of residual cell DNA
    Patent number: 10655108
    Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: May 19, 2020
    Assignee: Seqirus UK Limited
    Inventors: Jens-Peter Gregersen, Holger Kost
  • INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS
    Publication number: 20160158340
    Abstract: An immunological composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in call culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g., a matrix M1 fragment with a molecular weight of less than 20 kDa. The composition may be a subunit vaccine comprising purified surface glycoproteins.
    Type: Application
    Filed: December 4, 2015
    Publication date: June 9, 2016
    Inventors: Michael Broeker, Holger Kost
  • METHOD FOR DETERMINING THE CONCENTRATION OF VIRUS PARTICLES/VIRUS ANTIGENS
    Publication number: 20140322700
    Abstract: The invention provides a method for determining the concentration of virus particles and/or virus antigens in a sample. In particular, the invention relates to determining the concentration of influenza virus particles/influenza virus antigens in a sample. The invention further relates to the use of an ion-exchange matrix for the determination of the concentration of virus particles and/or virus antigens in a sample.
    Type: Application
    Filed: May 21, 2014
    Publication date: October 30, 2014
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Holger KOST
  • ANALYSIS OF DNA BY MEANS OF CAPILLARY ELECTROPHORESIS
    Publication number: 20110117127
    Abstract: The present invention relates to a method for detecting nucleic acids, wherein a sample to be analyzed for the presence of nucleic acids is separated by capillary electrophoresis. The conditions of sample injection and separation allow for an extremely high sensitivity of the method, which can be applied, e.g. for quality control purposes in the determination or the presence, quantity and/or size of genomic DNA contaminants in samples comprising proteins for therapy or vaccination.
    Type: Application
    Filed: March 27, 2009
    Publication date: May 19, 2011
    Applicant: NOVARTIS AG
    Inventors: Holger Kost, Simon Ramseger
  • Influenza Vaccines Containing Hemagglutinin and Matrix Proteins
    Publication number: 20110027314
    Abstract: An immunogenic composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in cell culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g. a matrix M1 fragment with a molecular weight of less than 2 OkDa. The composition may be a subunit vaccine comprising purified surface glycoproteins.
    Type: Application
    Filed: January 26, 2007
    Publication date: February 3, 2011
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG
    Inventors: Michael Broeker, Holger Kost
  • CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA
    Publication number: 20090304729
    Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
    Type: Application
    Filed: November 1, 2006
    Publication date: December 10, 2009
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG
    Inventors: Jens-Peter Gregersen, Holger Kost
  • Method For Determining The Concentration of Virus Particles/Virus Antigens
    Publication number: 20090202983
    Abstract: The invention provides a method for determining the concentration of virus particles and/or virus antigens in a sample. In particular, the invention relates to determining the concentration of influenza virus particles/influenza virus antigens in a sample. The invention further relates to the use of an ion-exchange matrix for the determination of the concentration of virus particles and/or virus antigens in a sample.
    Type: Application
    Filed: January 12, 2007
    Publication date: August 13, 2009
    Inventor: Holger Kost